Immune Modulation and Immunotherapy in Solid Tumors: Mechanisms of Resistance and Potential Therapeutic Strategies

被引:2
作者
Giri, Suman [1 ]
Lamichhane, Gopal [2 ]
Pandey, Jitendra [3 ]
Khadayat, Ramesh [4 ]
Sindhu, K. C. [5 ]
Devkota, Hari Prasad [6 ,7 ]
Khadka, Dipendra [8 ,9 ]
机构
[1] Purbanchal Univ, Asian Coll Adv Studies, Lalitpur 44700, Nepal
[2] Oklahoma State Univ, Dept Nutr Sci, Stillwater, OK 74078 USA
[3] Univ Hawaii Manoa, Dept Chem, 2545 McCarthy Mall, Honolulu, HI 96822 USA
[4] Patan Hosp, Patan Acad Hlth Sci, Lalitpur 44700, Nepal
[5] Tribhuwan Univ, Chitwan Med Coll, Dept Pharmacol, Bharatpur 05, Chitwan 44200, Nepal
[6] Kumamoto Univ, Grad Sch Pharmaceut Sci, Oehonmachi 5-1,Chuo Ku, Kumamoto 8620973, Japan
[7] Kumamoto Univ, Headquarters Admiss & Educ, Kurokami 2-39-1,huo Ku, Kumamoto 8608555, Japan
[8] Wonkwang Univ, NADIANBIO Co Ltd, Business Incubat Ctr R201, Sch Med, Iksan 54538, Jeonbuk, South Korea
[9] KHAS Hlth Pvt Ltd, Dhangadhi 04, Kailali 10910, Nepal
关键词
immune cells; tumor microenvironment; immune modulation; immunotherapy; therapeutic resistance; emerging strategies; therapeutic outcomes; REGULATORY T-CELLS; B-CELLS; SUPPRESSOR-CELLS; DENDRITIC CELLS; CANCER; MACROPHAGES; ACTIVATION; VACCINES; PATHWAY; BIOMARKERS;
D O I
10.3390/ijms26072923
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Understanding the modulation of specific immune cells within the tumor microenvironment (TME) offers new hope in cancer treatments, especially in cancer immunotherapies. In recent years, immune modulation and resistance to immunotherapy have become critical challenges in cancer treatments. However, novel strategies for immune modulation have emerged as promising approaches for oncology due to the vital roles of the immunomodulators in regulating tumor progression and metastasis and modulating immunological responses to standard of care in cancer treatments. With the progress in immuno-oncology, a growing number of novel immunomodulators and mechanisms are being uncovered, offering the potential for enhanced clinical immunotherapy in the near future. Thus, gaining a comprehensive understanding of the broader context is essential. Herein, we particularly summarize the paradoxical role of tumor-related immune cells, focusing on how targeted immune cells and their actions are modulated by immunotherapies to overcome immunotherapeutic resistance in tumor cells. We also highlight the molecular mechanisms employed by tumors to evade the long-term effects of immunotherapeutic agents, rendering them ineffective.
引用
收藏
页数:31
相关论文
共 199 条
[1]   Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Immunotherapy: A Promising Breakthrough in Cancer Therapeutics [J].
Abaza, Abdelrahman ;
Idris, Faten Sid ;
Shaikh, Humna Anis ;
Vahora, Ilma ;
Moparthi, Kiran Prasad ;
Al Rushaidi, Majdah T. ;
Muddam, Meghana Reddy ;
Obajeun, Omobolanle A. ;
Jaramillo, Arturo P. ;
Khan, Safeera .
CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (09)
[2]   The opposing roles of CD4+ T cells in anti-tumour immunity [J].
Ahrends, Tomasz ;
Borst, Jannie .
IMMUNOLOGY, 2018, 154 (04) :582-592
[3]   Contribution to Tumor Angiogenesis From Innate Immune Cells Within the Tumor Microenvironment: Implications for Immunotherapy [J].
Albini, Adriana ;
Bruno, Antonino ;
Noonan, Douglas M. ;
Mortara, Lorenzo .
FRONTIERS IN IMMUNOLOGY, 2018, 9
[4]   Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies [J].
Aldea, Mihaela ;
Andre, Fabrice ;
Marabelle, Aurelien ;
Dogan, Semih ;
Barlesi, Fabrice ;
Soria, Jean-Charles .
CANCER DISCOVERY, 2021, 11 (04) :874-899
[5]   Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma [J].
Amaria, Rodabe ;
Knisely, Anne ;
Vining, David ;
Kopetz, Scott ;
Overman, Michael J. ;
Javle, Milind ;
Antonoff, Mara B. ;
Tzeng, Ching-Wei D. ;
Wolff, Robert A. ;
Pant, Shubham ;
Lito, Kathryn ;
Rangel, Kelly ;
Fellman, Bryan ;
Yuan, Ying ;
Lu, Karen H. ;
Sakellariou-Thompson, Donastas ;
Haymaker, Cara L. ;
Forget, Marie-Andree ;
Hwu, Patrick ;
Bernatchez, Chantale ;
Jazaeri, Amir A. .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (02)
[6]   Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups [J].
Andrews, Lawrence P. ;
Yano, Hiroshi ;
Vignali, Dario A. A. .
NATURE IMMUNOLOGY, 2019, 20 (11) :1425-1434
[7]   Therapeutic cancer vaccines revamping: technology advancements and pitfalls [J].
Antonarelli, G. ;
Corti, C. ;
Tarantino, P. ;
Ascione, L. ;
Cortes, J. ;
Romero, P. ;
Mittendorf, E. A. ;
Disis, M. L. ;
Curigliano, G. .
ANNALS OF ONCOLOGY, 2021, 32 (12) :1537-1551
[8]   Macrophages: Their role, activation and polarization in pulmonary diseases [J].
Arora, Shweta ;
Dev, Kapil ;
Agarwal, Beamon ;
Das, Pragnya ;
Syed, Mansoor Ali .
IMMUNOBIOLOGY, 2018, 223 (4-5) :383-396
[9]   Mechanisms of Cancer Resistance to Immunotherapy [J].
Bai, Rilan ;
Chen, Naifei ;
Li, Lingyu ;
Du, Nawen ;
Bai, Ling ;
Lv, Zheng ;
Tian, Huimin ;
Cui, Jiuwei .
FRONTIERS IN ONCOLOGY, 2020, 10
[10]   Myeloid-derived suppressor cells as intruders and targets: clinical implications in cancer therapy [J].
Baniyash, Michal .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2016, 65 (07) :857-867